tirzepatide vs semaglutide head to head Trial Results Tirzepatide vs. Semaglutide for Weight

Other significant safety considerations include a history of pancreatitis, acute kidney injury risk, diabetic retinopathy complications in patients with type 2 diabetes, gallbladder disease, hypoglycemia risk in patients using other diabetes medications, and mental health monitoring for mood changes or suicidal ideation

With the loss of exclusivity, several companies, including Sandoz, Apotex, Teva, Taro, Vimy Pharma, Hims & Hers, and Biocon, have filed applications to launch generic versions of semaglutide, but they are pending Health Canadas regulatory approval

Third, the majority of trials had relatively short post-discontinuation follow-up durations (often 3 to 12 months), limiting the understanding of long-term weight trajectories

Spend Time in Nature: Even a short walk outside can help reduce stress levels